DCTH

Delcath reported Q3 2025 earnings with $20.6 million in revenue and a net income of $0.8 million. The company released its Q4 2025 earnings, reporting revenue of $20.73 million and an EPS of -$0.05, and announced record annual revenue of $85.2 million for 2025. The CHEMOSAT Hepatic Delivery System was included as a recommended liver-directed regional therapy option in the Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline. Delcath reported Q1 2026 results with $25.0 million in revenue but posted a net loss of $1.1 million and reiterated its full-year 2026 revenue guidance of at least $100 million. New data on percutaneous hepatic perfusion with melphalan in liver-dominant metastatic breast cancer was presented at the ESMO Breast Cancer 2026 congress. The CHEMOSAT Hepatic system was recommended for liver treatment, and the results from the Phase 2 CHOPIN trial were published in The Lancet Oncology.